These therapeutic agents have exhibited significant clinical benefits in a range of malignancies, including melanoma, non-small cell lung cancer, and colorectal cancer.7–12 PD-1, a type I transmembrane protein expressed on T cells, B cells, and NK cells, attenuates T cell activity upon binding to its ligand, PD-L1. The gene discussed is PDCD1; the disease is melanoma.